IRIS
CAPRANZANO, PIERA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.866
AS - Asia 5.202
EU - Europa 4.157
SA - Sud America 747
AF - Africa 583
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 6
Totale 20.569
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.540
SG - Singapore 2.766
CN - Cina 1.376
RU - Federazione Russa 1.325
IE - Irlanda 862
BR - Brasile 626
UA - Ucraina 594
IT - Italia 520
VN - Vietnam 485
CI - Costa d'Avorio 330
FR - Francia 302
CA - Canada 265
KR - Corea 165
SE - Svezia 132
NG - Nigeria 122
GB - Regno Unito 103
IN - India 93
DE - Germania 80
BD - Bangladesh 59
HK - Hong Kong 46
AR - Argentina 45
SN - Senegal 45
NL - Olanda 42
IQ - Iraq 36
PL - Polonia 36
MX - Messico 34
ZA - Sudafrica 33
ES - Italia 32
AT - Austria 25
UZ - Uzbekistan 25
FI - Finlandia 21
ID - Indonesia 21
BE - Belgio 20
CH - Svizzera 20
EC - Ecuador 20
PK - Pakistan 17
JP - Giappone 16
TR - Turchia 16
VE - Venezuela 16
GR - Grecia 14
MA - Marocco 13
BJ - Benin 10
IR - Iran 10
PE - Perù 8
PH - Filippine 8
UY - Uruguay 8
CL - Cile 7
CO - Colombia 7
JO - Giordania 7
KE - Kenya 7
NP - Nepal 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
RS - Serbia 6
SA - Arabia Saudita 6
TN - Tunisia 6
DZ - Algeria 5
EU - Europa 5
MY - Malesia 5
AZ - Azerbaigian 4
HN - Honduras 4
LT - Lituania 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
IL - Israele 3
KG - Kirghizistan 3
OM - Oman 3
SV - El Salvador 3
AU - Australia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
JM - Giamaica 2
LB - Libano 2
LY - Libia 2
NI - Nicaragua 2
TV - Tuvalu 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GM - Gambi 1
GT - Guatemala 1
IM - Isola di Man 1
KI - Kiribati 1
KN - Saint Kitts e Nevis 1
Totale 20.556
Salva come PNG Salva come JPEG
Città #
Singapore 1.545
Dallas 1.445
Santa Clara 1.151
Dublin 861
Jacksonville 804
San Jose 703
Chandler 685
Houston 509
Ashburn 474
Moscow 472
Boardman 403
Abidjan 330
Nanjing 245
Chicago 241
Hefei 241
Lauterbourg 222
Andover 214
Cambridge 213
Lawrence 213
Toronto 175
Seoul 165
Catania 145
Beijing 144
Des Moines 142
Los Angeles 139
Dong Ket 125
Ho Chi Minh City 125
Civitanova Marche 105
Hanoi 89
Nanchang 83
Wilmington 83
Council Bluffs 79
San Mateo 76
Abuja 75
Hebei 63
São Paulo 63
New York 61
Shenyang 52
Ottawa 48
Jiaxing 47
Dakar 45
Saint Petersburg 45
Buffalo 43
Tianjin 39
Changsha 38
Lagos 38
The Dalles 37
Columbus 34
Hong Kong 34
Bremen 31
Washington 31
Amsterdam 27
Brooklyn 25
Phoenix 25
Warsaw 25
Atlanta 22
Pune 22
Rio de Janeiro 22
Seattle 22
Montreal 21
Norwalk 21
Brussels 20
Orem 20
Da Nang 19
London 19
Milan 19
Johannesburg 18
Chennai 17
Denver 17
Hangzhou 17
Kunming 17
Ningbo 17
Baghdad 16
Belo Horizonte 16
Falls Church 16
Mumbai 16
San Francisco 16
Stockholm 16
Boston 15
Haiphong 15
Helsinki 15
Tokyo 15
Jinan 14
Redondo Beach 14
Guangzhou 13
Rome 12
Den Haag 11
Elk Grove Village 11
Frankfurt am Main 11
Poplar 11
Cotonou 10
Mexico City 10
Guayaquil 9
Nuremberg 9
Port Harcourt 9
Porto Alegre 9
Santos 9
Zhengzhou 9
Charlotte 8
Curitiba 8
Totale 14.245
Salva come PNG Salva come JPEG
Nome #
Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients 560
1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds versus Everolimus-Eluting Stents: a Propensity Matched Comparison of the GHOST-EU and XIENCE V USA Registries 226
A Risk Model for Prediction of One-Year Mortality in Patients Undergoing MitraClip Implantation 185
A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score 165
1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry 165
Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement 163
Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. 144
Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System 144
A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. 142
A comparison between Endeavor and Endeavor Resolute drug-eluting stents: outcome at six months follow up 140
Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 31 Studies and 17,882 Patients 138
A comparison between Endeavor and Endeavor Resolute drug-eluting coronary stents: outcomes at six month follow up 136
Acute Left Atrial Spontaneous Echo Contrast and Suspicious Thrombus Formation Following Mitral Regurgitation Reduction With The MitraClip System 135
Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement 135
Early cardiovascular remodelling in Fabry disease 134
Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) Real-World Registry 132
Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. 132
A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in Left Main Patients with Intermediate Global Risk 130
Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. 127
Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry 126
Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair 125
The treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds 123
Prevention of Acute Kidney Injury with the RenalGuard System in patients undergoing Transcatheter Aortic Valve Implantation: The PROTECT-TAVI trial 123
Current status of transcatheter valve therapy in Europe: results from an EAPCI survey 122
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study 122
Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts 121
Appraisal of key trials in aortic and mitral fields 121
Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation) 121
Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems 117
Cigarette Smoking is Associated with a Dose-Response Effect in Clopidogrel Treated Patients with Diabetes Mellitus and Coronary Artery Disease: Results of a Pharmacodynamic Study 117
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement 113
Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update 113
Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists 113
A Novel Mechanism by Which MitraClip Implantation May Favorably Alter the Natural History of Left Ventricular Remodeling in Patients with Mitral Regurgitation: Proposed Role of the Ventricular-Valvular Loop 112
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: Development and internal validation of the PSP score 112
Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry 107
Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture 106
Feasibility and Predictors of Early Discharge After Percutaneous Edge-to-Edge Mitral Valve Repair 106
Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. 106
Early discharge in acute myocardial infarction after clinical and angiographic risk assessment 105
Bioresorbable vascular scaffold in patients with complex coronary artery disease. 105
Association of Tricuspid Regurgitation With Clinical and Echocardiographic Outcomes After Percutaneous Mitral Valve Repair With the MitraClip System: Thirty-Day and Twelve-Month Follow-up From the GRASP Registry 104
Retrograde Approach for Chronic Total Occlusion Percutaneous Coronary Intervention: The Paradox of Choice 103
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. 102
Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery 101
Effects of Cangrelor in Coronary Artery Disease Patients With and Without Diabetes Mellitus: An In Vitro Pharmacodynamic Investigation 101
Transcatheter Aortic-Valve Replacement 100
Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry 100
Clinical implication of different plaque distribution patterns in distal left main coronary artery 100
EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention 98
Risk stratification for secondary prevention with ticagrelor and aspirin: a closer look to patient subsets from the PEGASUS-TIMI 54 trial 98
Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device Iterations 98
Parenteral Anticoagulant Agents in PCI 97
Antithrombotic Management of Elderly Patients With Coronary Artery Disease 96
Management issues of chronic therapy with non-vitamin K oral anticolagulants or antiplatelet agents: different or alike? 96
Functional profile of the platelet P2Y12 receptor signaling pathway in patients with diabetes mellitus and coronary artery disease 96
Progresses in interventional cardiology: focus on patent foramen ovale, coronary intervention, antithrombotic pharmacology, and more 96
Feasibility and Outcomes of Repeat Percutaneous Edge-to-Edge Mitral Valve Repair Procedures in Patients at High Risk for Surgery 95
Haemostatic Profiles Assessed by Thromboelastography in Patients with End-Stage Renal Disease 95
Risk stratification after ST-elevation myocardial infarction 95
Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE registry) 95
Is the metallic stent a safe treatment for bioresorbable scaffold failure? Insights from optical coherence tomography 94
Update on clinical evidence (Part II): a summary of the main post market studies 94
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome 93
Gestione della terapia antitrombotica nei pazienti con sanguinamento dopo angioplastica coronarica [Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention] 91
Simultaneous plaque rupture and erosion in the same atheroma: insights from two and three-dimensional optical coherence tomography 91
Serum cotinine levels are associated with increased clopidogrel-induced antiplatelet effects 91
Short and mid-term benefits of coronary stent system with nanothin Polyzene-F in acute coronary syndromes: preliminary result 91
Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary PCI 90
Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease 90
P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis 89
Early and Midterm Outcomes of Bioresorbable Scaffolds for Ostial Coronary Lesions: Insights from the GHOST-EU Registry 89
Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients. 89
One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy? 88
Real world safety and efficacy of the janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting Stent (TEST) registry 88
Procedural management of patients with advanced heart failure undergoing MitraClip implantation (from the GRASP registry) 88
Strategies and Outcomes of Repeat Mitral Valve Interventions After Failed MitraClip Therapy 88
Mid-term clinical outcome of Catania coronary stent system with nanothin Polyzene-F in a real world unselected population: preliminary results 88
Current status of transcatheter mitral valve therapy in Europe: results from an EAPCI survey (Part II) 88
Revascularization vs. Optimal Medical Therapy in Women with NSTE-ACS 88
Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry) 88
Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. 87
Impact of Residual Platelet Reactivity on reperfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention 87
MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement 87
Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for LefT main Artery registry substudy). 86
Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality? 86
Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry 86
Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study 85
Clinical development of selective anticoagulants: a state of the art 85
Percutaneous Coronary Intervention With Everolimus-Eluting Bioresorbable Vascular Scaffolds In Routine Clinical Practice: Early and Mid-Term Outcomes From The European Multicenter GHOST-EU Registry 85
Drug-Eluting Stent for Left Main Coronary Artery Disease: The DELTA Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment 85
Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients 85
Plaque distribution patterns in distal left main coronary artery to predict outcomes after stent implantation 85
Self-apposing STENTYS stent in acute myocardial infarction 85
Is isolated disease of the ostium left anterior descending or circumflex artery a distal left main pathology? 85
Bioresorbable everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multi-center GHOST-EU registry 84
Capitolo 2 - Diagnostica cardiovascolare 84
PHARMACODYNAMIC EFFECTS OF DIFFERENT ASPIRIN DOSING REGIMENS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CORONARY ARTERY DISEASE 84
Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry 84
[ANMCO/GISE/SICCH Inter-Society Consensus Document: Antithrombotic therapy after surgery or structural interventional procedures for valvular heart diseases: how to treat postoperative complications] 83
Totale 11.149
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.684
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.684
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021158 0 0 0 0 0 0 0 0 0 0 0 158
2021/20221.478 169 231 2 24 256 15 223 55 116 1 20 366
2022/20232.435 219 51 19 192 333 437 7 380 679 10 75 33
2023/20241.207 63 216 60 87 51 268 31 50 3 29 199 150
2024/20254.141 32 584 281 173 1.041 412 62 147 381 434 250 344
2025/20268.292 512 442 1.575 422 1.452 1.477 1.152 179 408 295 227 151
Totale 20.960